Plandai Shares Hit New Year-High Despite Market Slump

Plandai Shares Hit New Year-High Despite Market Slump 
BALTIMORE, MD -- (Marketwired) -- 08/22/13 --  Goldman Small Cap
Research, a stock market research firm focused on the small cap and
micro cap sectors, notes that shares of Plandai Biotechnology Inc.
(OTCQB: PLPL) closed at a new 52-week high yesterday, despite the
current stock market slump. The shares may be further bolstered by
results of a research study conducted by The Coca-Cola Company
indicating that drinking polyphenol rich juice may have benefits
associated with a positive change in a major protein that affects
arterial health. These findings should be viewed as a positive event
and as corroborating third-party evidence from the world's leading
beverage producer and thus a boon to Plandai. The Company plans to
introduce highly bioavailable extract products under the Company's
Phytofare(TM) line that specifically contain these polyphenols which
can be used in juices and other beverages. 
Polyphenols are derived from natural extracts and have been the
subject of extensive research due to high antioxidant activity and
demonstrated capability to eliminate free radicals, or polluted
cells. They are commonly found in green tea extracts, or green tea
gallate catechin extracts, and carotenoid botanical extracts found in
tomatoes and other 'colorful' vegetables. 
The aforementioned study was conducted in a partnership with the
University of Glasgow and Mosaiques Diagnostics, GmbH. Results
demonstrated that the levels of 27 polypeptides, which are protein or
amino acid chains in the arteries and elsewhere, increased by nearly
4 times in experimental candidates that consumed the polyphenol rich
juices over time. Therefore, the study demonstrated that drinking
green tea extract or carotenoid extract appears to improve arterial
function at the molecular level. 
Plandai's Phytofare(TM) Catechin Complex and Carotenoid Complex have
been formulated with a proprietary process that will enable the
release of more of these polyphenol compounds versus the competitors.
This product differentiation is created with superior
bioavailability, or the measurement of an amount of a compound that
is absorbed into the bloodstream. Normal extracts produce 1-10%
bioavailability, while the Phytofare(TM) extract products have
 70% on average for bioavailability. 
Plandai is on target to begin production of the Phytofare(TM)
Catechin Complex in powder form, topical cream, gel tabs, and a
liquid by the end of 1Q14. The Company has partnered with several
distributors in the U.S., Europe and Africa to sell market and
distribute Plandai's Phytofare(TM) extracts in 1Q14 as well. 
Plandai's aggressive marketing campaign will reap major benefits from
the message that beverages and other products that utilize the
Phytofare(TM) products can provide superior levels of healthy
ingredients, such as the polyphenols mentioned above. This
differentiation should help the Company expand its market share and
generate strong results in 2014. 
Goldman Small Cap Research articles, reports, and updates on Plandai
as well as associated disclaimers and disclosures can be accessed or
downloaded in their entirety by visiting 
About Goldman Small Cap Research: Led by former Piper Jaffray analyst
and mutual fund manager Rob Goldman, Goldman Small Cap Research
produces sponsored and non-sponsored small cap and micro cap stock
research reports, articles, daily stock market blogs, and popular
investment newsletters. For more information, visit 
A Goldman Small Cap Research report is not intended as an offering,
recommendation, or a solicitation of an offer to buy or sell the
securities mentioned or discussed. Please read the report's full
disclosures and analyst background on our website before investing.
Neither Goldman Small Cap Research nor its parent is a registered
investment adviser or broker-dealer with FINRA or any other agency.
To download our research, view our disclosures, or for more
information, visit 
About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai
Biotechnology, Inc. and its subsidiaries develop highly bioavailable,
phytonutrient rich extracts, which are being utilized to deliver a
new family of drugs to safely and affordably treat a multitude of
diseases and conditions. Plandai Biotechnology controls every aspect
of the process, from growing the raw materials on its farms in South
Africa, to producing the patented pending Phytofare(TM) extracts
in-house allowing the Company to guarantee the continuity of supply
as well as quality control throughout Targeted industries for the
Company's products include food and beverage, cosmeceutical,
wellness, nutraceutical, anti-aging, and pharmaceutical. For more
information, please visit 
Goldman Small Cap Research
Rob Goldman
Press spacebar to pause and continue. Press esc to stop.